VACCINES-EUROPE
21.1.2020 07:37:09 CET | Business Wire | Press release
At an event held in the European Parliament today, policymakers noted the lack of progress made by EU Member States towards the EU’s 75% target for seasonal influenza vaccination coverage rates among older-age and at-risk groupsi , first adopted in the EU Council Recommendation on seasonal influenza vaccination in 2009.ii
Speakers from the European Commission, European Parliament, European Centre for Disease Prevention and Control (ECDC) and World Health Organisation (WHO) all agreed on the need to seize the opportunity presented by the 10-year milestone of the 2009 Recommendation to renew efforts to boost coverage rates and address the major public health challenges associated with seasonal influenza.
Building on a new study on public perceptions of seasonal influenza disease and vaccination in four EU countriesiii and leveraging some national best practices, panellists stressed the need for all influenza stakeholders to gather in simultaneously addressing influenza vaccine confidence, convenience and complacency issues.
Potential solutions were discussed and identified, which would help addressing specific challenges and make progress towards the ten-year-old 75% seasonal influenza vaccination target, such as:
- Voluntary exchange of best practices between EU countries on how to increase seasonal influenza vaccination rates. This could be done as part of the EU State of Health initiative cycle.iv Following the publication of Country Health Profiles 2019, the European Commission could establish voluntary exchanges between EU countries, in particular focusing on seasonal influenza vaccination policies and programmesv .
- EU guidance on data collection for seasonal influenza vaccine coverage rates. This should cover what should be collected, when and how . Currently, data is collected differently and at different times in various EU Member States, which creates an uneven and patchy picture across the EU. An EU Guidance on data collection will allow to monitor whether the EU’s 75% target has been met in all at risk or targeted groups as well as propose appropriate measures to achieve it.
- Measures to allow all competent healthcare professionals to provide vaccination in convenient locations. For example, by allowing vaccine administration in locations such as workplaces, community pharmacies and schools. Evidence shows that in countries where pharmacists can administer vaccines, the number of people vaccinated increases.vi The EU has a role to play in sharing best practices and providing guidance, and EU Member States will need to introduce appropriate legislations and policies to implement these practices.
- Further work by EU Member States, as well as the EU and WHO, needs to improve knowledge/education of and confidence in, vaccines among both citizens and healthcare professionals. In some countries, as many as 36.4% of GPs do not believe that the seasonal influenza vaccination is important, and elsewhere the percentage of the general public who believe that it is important is as low as 40.4%. Countries such as Spain and Portugal showcase best practices, with public confidence rates of almost 80%.vii
- All influenza actors should join forces in, for example, a multi-stakeholder coalitionviii , and launch an European Influenza Awareness Day , that would help to boost influenza vaccination confidence.
MEP Dolors Montserrat (EPP, ES), co-host of the event and former Spanish Health Minister, said that “to progress towards a broader vaccination coverage, especially for people with chronic diseases, we need to:
- Raise awareness among healthcare professionals, and policy makers on the problem to build trust in institutions and providers of vaccines;
- Empower patients to be correctly informed and participate in the decision making process on the adequate and most cost-effective therapies for their health;
- Fight the fake news and the misinformation campaigns through promoting sources of reliable information about vaccination, exposure to positive media messages.”
“The EU has given vaccination a lot of political attention recently – not least through the 2018 Council Recommendation on Strengthened Cooperation Against Vaccine-Preventable Diseases, the EU Joint Action on Vaccination, and the 2019 Global Vaccination Summit. But dwindling seasonal influenza vaccination coverage rates show that much more needs to be done – both at EU and national level” said Magdalena R. de Azero, Executive Director of Vaccines Europe, which organised the event. Ms de Azero concluded: “This event underlines the need for institutions, governments, healthcare professionals and industry to work together to address this challenge.”
Notes
Seasonal influenza poses a significant but often under-recognised challenge to EU health systems. Compared to other infectious diseases, it has the highest impact in terms of mortality and incidence and is estimated to cause up to 70,000 deaths in the EU each year, particularly among older age groups.ixx Its impact is particularly acute among the elderly and other at-risk groups.
Latest EU data (2017, published in 2019) shows that no EU Member State has reached the 75% target for coverage rates. In fact, many countries have seen rates decline, some going as low as single digits (Latvia 6.9%, Estonia 4.8%). The best-in-class EU country, the UK, has seen rates consistently around 70% in recent years (currently 72.6%).xi
About Vaccines Europe
Formed in 1991, Vaccines Europe is a specialised group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) that represents major innovative research-based vaccine companies as well as small and medium-sized enterprises operating in Europe which account for a large share of human vaccines used worldwide.
i
As defined by ECDC. https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/risk-groups
ii
https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF
iii
Full study to be published in the near future. Presented by Professor Frederic Bouder of the University of Stavanger.
iv
https://ec.europa.eu/health/state/summary_en
v
https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_services_en.pdf
.
vi
https://www.vaccinestoday.eu/stories/does-pharmacy-vaccination-increase-overall-uptake/
vii
https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_confidence_en.pdf
viii
For example: https://www.immunize.org/
ix
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2018.23.16.17-00454
x
https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet
xi
https://ec.europa.eu/eurostat/web/products-eurostat-news/product/-/asset_publisher/VWJkHuaYvLIN/content/DDN-20191209-2
View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005574/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 12:00:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission
KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 12:00:00 CEST | Press release
KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
